Beauty’s Toxic Bargain Is Finally on Trial -By Fransiscus Nanga Roka

The US beauty industry marketed a jar of chemical hair relaxer as confidence, convenience and conformity in a jar. That deal is now being fought in court: thousands of women are claiming that the manufacturers were able to profit by not directly telling them that repeated use could lead to a higher risk of uterine and ovarian cancers, which has led to at least dozens of lawsuits set to go in 2026.

That who, indelibly linked to race and gender. Just how much simpler was it to market chemical relaxers to Black women specifically when they became excluded from workplaces and schools that perceived their natural, coily black hair to be unprofessional? It is not only that the plaintiffs are simply a group of consumers who bought defective products; they are women, making a claim that they have been up against a racial beauty standard that made science experiments out of their bodies.

What Is in re: Hair Relaxer Marketing, Sales Practices and Products Liability Litigation, MDL No. 3060 The federal cases are consolidated under Judge Mary M. Rowland of the Northern District of Illinois As of June 1, 2026 the US Judicial Panel on Multidistrict Litigation listed a total of 11,723 pending actions as well as another 15,898 historical filings, it has become one of America’s largest active product liability lawsuits.

The where and when of that is so much bigger than a courtroom in Chicago. The alleged contacts were pretty much everywhere in residences and salons throughout the country often lasting years or even decades. Alarm bells have rung about hormone-related cancers showed by epidemiological studies, and litigation began to snowball.

The why, is based on troubling and therefore should be disclosed scientific truths. In the most recent analysis from the ongoing prospective cohort Sister Study by NIH, which includes over 50 published papers to date on different health conditions and chemicals in hair products, researchers found that women frequently reporting straightener use—more than four times within the past year were more than twice as likely to develop uterine cancer than non-users. Estimates of risk by age 70 of developing uterine cancer was approximately 1.64% in non-users and about 4.05% in frequent users, the researchers reported. (National Institutes of Health (NIH)) A second prospective analysis found an increased risk with straightener or relaxer use, reporting a hazard ratio of 2.19 with a very wide confidence interval (CI).

However, association does not constitute proof that a specific product was responsible for the cancer of a specific woman. This is how the litigation matters: Plaintiffs have to link exposure, ingredients, biological mechanisms and personal diagnoses; defendants can argue dose reconstruction, confounding factors and expert methodologies. The studies did not demonstrate that all relaxers, or brands or ingredients within them have the same risk. Until a jury verdict is issued or money is exchanged, the manufacturers’ liability is merely alleged.

But that uncertainty is not a corporate get out of jail free card. Marketing products that are meant to be used repeatedly, over a life-time, on areas of absorbent and sometimes sensitised skin, equates ignorance with commercial strategy. A warning which is postponed until clear causation is incontrovertibly positive then, is not consumer-protection—it is outsourced experimentation.

Three interventions are urgent. Instead, the FDA is going to insist on full ingredient transparency, independent endocrine-disruption testing and strong risk warning statements – not mere cosmetic packaging fine prints. Second, courts must require the preservation and disclosure of internal toxicology, formulation changes, complaints and marketing efforts while challenging expert opinions from both sides with emphasis on the authenticity and credibility of testimony. Third, Congress should establish a national cosmetic-use and cancer database, fund research focused on Black women survivors, and ban discrimination using hair to coerce women into chemical compliance.

The litigation raises a philosophical inquiry almost more than one of compensation: Who carries the weight of scientific uncertainty, the corporation that engineered and marketed the exposure or the women whose organs may have paid its sub rosa toll?

Fransiscus Nanga Roka

Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia